Production (Stage)
Cyclacel Pharmaceuticals, Inc.
CYCC
$0.4121
$0.053114.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 57.62% | 50.29% | 45.63% | 26.34% | 13.96% |
| Total Depreciation and Amortization | -84.00% | -80.65% | -58.06% | -38.71% | -19.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 68.01% | -60.47% | -48.46% | -32.03% | -21.85% |
| Change in Net Operating Assets | -151.07% | -46.87% | -63.77% | 159.88% | 2,113.71% |
| Cash from Operations | -10.48% | 50.41% | 39.30% | 43.29% | 53.45% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | 100.00% | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,016.97% | 645.76% | 7,790.22% | 333.63% | -67.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | 75.12% | 50.25% | 24.88% |
| Other Financing Activities | -113.92% | -- | -- | -- | -- |
| Cash from Financing | 1,309.89% | 822.41% | 6,712.84% | 386.01% | -72.68% |
| Foreign Exchange rate Adjustments | -150.72% | -124.09% | 235.51% | 346.75% | 199.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.55% | 98.39% | 83.32% | 77.98% | 52.55% |